Vaccine evaluation: Lessons from a meningococcal B vaccine

Archives of Disease in Childhood

Volumn 100, Issue 6, 2015, Pages 514-516

  Sarfatti, Avishay ^a   Martinón Torres, Federico ^b   Nadel, Simon ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b University Hospital of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCAL B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; 4CMENB VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC MENINGITIS; HERD IMMUNITY; HUMAN; MENINGOCOCCEMIA; MENINGOCOCCOSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM; VACCINATION; ADVISORY COMMITTEE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG SCREENING; ECONOMICS; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; PREVENTIVE HEALTH SERVICE;

ADVISORY COMMITTEES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG EVALUATION; GREAT BRITAIN; HUMANS; IMMUNIZATION PROGRAMS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES;

EID: 84926245204     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306030     Document Type: Article

References (19)

1. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EMA/ CHMP/669278/2012; 15 November 2012.
2. Meningococcal B vaccine: JCVI position statement.Published 21/03/2014. https://www.gov.uk/ government/publications/ meningococcal-b-vaccine-jcvi-position-statement
3. Hall AJ. The United Kingdom Joint Committee on Vaccination and Immunisation. Vaccine 2010;28 (Suppl 1):A54-7.
4. Brysona M, Duclosb P, Jollya A, et al. A global look at national Immunization Technical Advisory Groups. Vaccine 2010;28(Suppl 1):A13-17.
5. Christensen H, Hickman M, Edmunds WJ, et al. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013;31:2638-46.
6. Joint Committee on Vaccination and Immunisation. JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK. Department of Health, 2013. www.gov.uk/ government/publications/jcvi-interim-positionstatement- on-the-use-of-bexseromeningococcal-bvaccine- in-the-uk
7. Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ 2014;349:g5725.
8. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009;27(Suppl 2):B20-9.
9. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006;25:494-501.
10. Pouwels KB, Hak E, van der Ende A, et al. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 2013;9:1129-38.
11. Tu HA, Deeks SL, Morris SK, et al. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Vaccine 2014;32:5436-46.
12. Campbell H, Andrews N, Borrow R, et al. Updated post-licensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-7.
13. Trotter CL, Edmunds WJ. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med Decis Making 2006;26:38-47.
14. Wright C, Wordsworth R, Glennie L. Counting the cost of meningococcal disease: scenarios of severe meningitis and septicemia. Paediatr Drugs 2013;15:49-58.
15. Grimwood K, Anderson P, Anderson V, et al. Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Arch Dis Child 2000;83:111-16.
16. Rappuoli R, Pizza M, Del Giudice G, et al. Vaccines, new opportunities for a new society. Proc Natl Acad Sci USA 2014;111:12288-93.
17. Joint Committee on Vaccination and Immunisation, Minute of the meeting on 4 June 2014. https://app.box.com/s/iddfb4ppwkmtjusir2tc/1/2199012147/ 19052160649/1
18. NICE clinical guideline 102. Bacterial meningitis and meningococcal septicaemia, Management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. Issued: June 2010.
19. Wolfe I, Thompson M, Gill P, et al. Health services for children in Western Europe. Lancet 2013;381:1224-34.